KRYSTAL

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

• Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with
  KRAS G12C mutation and known PD-L1 Tumor Proportion Score (TPS) score.
• Unresectable or metastatic disease.
• Not a candidate for definitive therapy (e.g., chemoradiation for locally advanced
  disease).
• PD-L1 >50%

• Prior systemic treatment for locally advanced or metastatic NSCLC including
  chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS
  G12C mutation (e.g., AMG 510).
• Radiation to the lung >30 Gy within 6 months prior to the first dose of study
  treatment.
• Active brain metastases. Patients are eligible if brain metastases are adequately
  treated and patients are neurologically stable (except for residual signs or symptoms
  related to the central nervous system [CNS] treatment) for at least 2 weeks prior to
  the first dose of study treatment without the use of corticosteroids or are on a stable or
  decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
• Carcinomatous meningitis.